Cargando…
Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
Hemophilia A (HA), a rare recessive X-linked bleeding disorder, is caused by either deficiency or dysfunction of coagulation factor VIII (FVIII) resulting from deleterious mutations in the F8 gene encoding FVIII. Over the last 4 decades, the methods aimed at determining the HA carrier status in fema...
Autores principales: | Dardik, Rima, Janczar, Szymon, Lalezari, Shadan, Avishai, Einat, Levy-Mendelovich, Sarina, Barg, Assaf Arie, Martinowitz, Uri, Babol-Pokora, Katarzyna, Mlynarski, Wojciech, Kenet, Gili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380558/ https://www.ncbi.nlm.nih.gov/pubmed/37511607 http://dx.doi.org/10.3390/ijms241411846 |
Ejemplares similares
-
Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
por: Dardik, Rima, et al.
Publicado: (2021) -
Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
por: Lalezari, Shadan, et al.
Publicado: (2021) -
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023) -
Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023) -
Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)